Literature DB >> 27119533

Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer.

Asta Bye1,2, Nima Wesseltoft-Rao3,4, Per Ole Iversen4,5, Grete Skjegstad3, Kirsten B Holven4,6, Stine Ulven3,4, Marianne J Hjermstad7,8.   

Abstract

Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35-79) years, 5 females, were followed for median 5.5 (1-12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m(2) and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia.

Entities:  

Keywords:  Adipokines; Advanced cancer; Cancer cachexia; Cytokines; Inflammation; Pancreatic cancer

Mesh:

Substances:

Year:  2016        PMID: 27119533     DOI: 10.1007/s12032-016-0768-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  45 in total

1.  Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool.

Authors:  Lene Thoresen; Irene Fjeldstad; Knut Krogstad; Stein Kaasa; Ursula G Falkmer
Journal:  Palliat Med       Date:  2002-01       Impact factor: 4.762

2.  Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters.

Authors:  I T L Lillegaard; L F Andersen
Journal:  Br J Nutr       Date:  2005-12       Impact factor: 3.718

3.  Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation.

Authors:  U Khalid; A Spiro; C Baldwin; B Sharma; C McGough; A R Norman; T Eisen; M E R O'Brien; D Cunningham; H J N Andreyev
Journal:  Support Care Cancer       Date:  2006-06-20       Impact factor: 3.603

4.  Symptoms in advanced pancreatic cancer are of importance for energy intake.

Authors:  Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad
Journal:  Support Care Cancer       Date:  2012-06-10       Impact factor: 3.603

Review 5.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

6.  Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones.

Authors:  Marita Fouladiun; Ulla Körner; Ingvar Bosaeus; Peter Daneryd; Anders Hyltander; Kent G Lundholm
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

7.  The prevalence of concern about weight loss and change in eating habits in people with advanced cancer.

Authors:  Jane B Hopkinson; David N M Wright; John W McDonald; Jessica L Corner
Journal:  J Pain Symptom Manage       Date:  2006-10       Impact factor: 3.612

8.  Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks.

Authors:  Barbara S van der Meij; Coline P Schoonbeek; Egbert F Smit; Maurizio Muscaritoli; Paul A M van Leeuwen; Jacqueline A E Langius
Journal:  Br J Nutr       Date:  2012-11-16       Impact factor: 3.718

9.  Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.

Authors:  Barry J Laird; Stein Kaasa; Donald C McMillan; Marie T Fallon; Marianne J Hjermstad; Peter Fayers; Pal Klepstad
Journal:  Clin Cancer Res       Date:  2013-08-12       Impact factor: 12.531

10.  Changes in nutritional status associated with unresectable pancreatic cancer.

Authors:  S J Wigmore; C E Plester; R A Richardson; K C Fearon
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  15 in total

1.  Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.

Authors:  Philip Bonomi; Marta Batus; Mary Jo Fidler; Jeffrey A Borgia
Journal:  Ann Transl Med       Date:  2017-03

2.  Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC).

Authors:  Nicholas Zdenkowski; George Radvan; Leanna Pugliese; Julie Charlton; Christopher Oldmeadow; Allison Fraser; Antonino Bonaventura
Journal:  Support Care Cancer       Date:  2017-02-04       Impact factor: 3.603

3.  Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.

Authors:  Mangala Hegde; Uzini Devi Daimary; Sosmitha Girisa; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-06

4.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

5.  ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.

Authors:  Jingxuan Yang; Zicheng Zhang; Yuqing Zhang; Xiaoling Ni; Guohua Zhang; Xiaobo Cui; Mingyang Liu; Can Xu; Qiang Zhang; Huiyun Zhu; Jie Yan; Vivian F Zhu; Yusheng Luo; John P Hagan; Zhaoshen Li; Jing Fang; Aminah Jatoi; Martin E Fernandez-Zapico; Lei Zheng; Barish H Edil; Michael S Bronze; Courtney W Houchen; Yi-Ping Li; Min Li
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

Review 6.  Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.

Authors:  Alexandra Moreira-Pais; Rita Ferreira; Paula A Oliveira; José A Duarte
Journal:  Biogerontology       Date:  2021-07-29       Impact factor: 4.277

Review 7.  Pancreatic cancer cachexia: three dimensions of a complex syndrome.

Authors:  Maximilian Kordes; Lars Larsson; Lars Engstrand; J-Matthias Löhr
Journal:  Br J Cancer       Date:  2021-03-19       Impact factor: 7.640

Review 8.  Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.

Authors:  Mohammad Aslam Aslam Khan; Shafquat Azim; Haseeb Zubair; Arun Bhardwaj; Girijesh Kumar Patel; Moh'd Khushman; Seema Singh; Ajay Pratap Singh
Journal:  Int J Mol Sci       Date:  2017-04-06       Impact factor: 5.923

9.  Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies.

Authors:  C Graham; R Chooniedass; W P Stefura; L Lotoski; P Lopez; A D Befus; A B Becker; K T HayGlass
Journal:  J Transl Med       Date:  2017-03-02       Impact factor: 5.531

10.  Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients.

Authors:  Ting Zhou; Bangyan Wang; Huiquan Liu; Kaixiang Yang; Sudip Thapa; Haowen Zhang; Lu Li; Shiying Yu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-01-25       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.